Upstream Bio Revenue

In the year 2025, Upstream Bio had annual revenue of $2.85M with 20.42% growth. Upstream Bio had revenue of $668.00K in the quarter ending December 31, 2025, with 8.97% growth.

Revenue (ttm)

$2.85M

Revenue Growth

+20.42%

P/S Ratio

188.39

Revenue / Employee

$38,053

Employees

Market Cap

537.67M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	2.85M	484.00K	20.42%
Dec 31, 2024	2.37M	-10.00K	-0.42%
Dec 31, 2023	2.38M	1.17M	96.37%
Dec 31, 2022	1.21M	-	-

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

UPB News

20 days ago - Upstream Bio Lead Drug Pivotal Trial Plan Follows Strong Phase 2 Data - Benzinga
21 days ago - Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
6 weeks ago - Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting - GlobeNewsWire
6 weeks ago - Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026 - GlobeNewsWire
7 weeks ago - Upstream Bio to Participate in Upcoming March Investor Conferences - GlobeNewsWire
2 months ago - Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns - Benzinga
2 months ago - Upstream Bio Shows Asthma Drug Cuts Attacks By 56%, Stock Reacts - Benzinga
2 months ago - Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma - GlobeNewsWire

More News